ABBV vs DDOG: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Datadog, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-09.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Datadog, Inc. · Technology
$200.16
+45.0% upside to fair value
Grade C
High Quality
QuantHub Verdict
DDOG has more upside to fair value
(+45.0%).
ABBV trades at a lower forward P/E
(83.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
DDOG |
| Current Price |
$197.69 |
$200.16 |
| Fair Value Estimate |
$210.22 |
$290.23 |
| Upside to Fair Value |
+6.3%
|
+45.0%
|
| Market Cap |
$349.7B |
$71.2B |
| Forward P/E |
83.3x
|
521.2x
|
| EV / EBITDA |
23.4x
|
415.7x
|
| Price / Sales |
5.7x
|
19.4x
|
| Price / FCF |
18.7x
|
66.0x
|
| Revenue Growth YoY |
+10.0%
|
+32.2%
|
| Gross Margin |
70.2%
|
79.9%
|
| Operating Margin |
26.7%
|
-0.7%
|
| Return on Equity |
-361.6%
|
3.8%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
1.51%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Datadog, Inc. is a leading cloud-based monitoring and analytics platform specializing in observability and security solutions for enterprise IT infrastructure. The company demonstrates high business quality with durable competitive moats driven by product integration, developer-centric design, and scale. Despite strong revenue growth of 27.8% year-over-year in fiscal 2025 and earnings growth of 1…
Accumulation Zones
| Metric |
ABBV |
DDOG |
| Zone Low |
$157.66 |
$217.67 |
| Zone High |
$178.69 |
$246.70 |
| In Buy Zone? |
No
|
Yes
|